Published by

Elsevier Ltd on behalf of International Society for Infectious Diseases.”
“Living Well with Epilepsy 11 called for further attention to stigma and its impact on people with epilepsy. In response, the South Carolina Health Outcomes Project on Epilepsy (SC HOPE) is examining the relationship between socioeconomic status, epilepsy severity, health care utilization, and quality of life in persons diagnosed with epilepsy. The current analysis quantifies perceived stigma reported by adults with epilepsy in relation to demographic, seizure-related, health, and psychosocial factors. It was found that reported levels of stigma were associated with interactions of seizure worry and employment status, TPCA-1 research buy self-efficacy and social support, and quality care and age at seizure onset. This information may be used to target and develop evidence-based interventions for adults with epilepsy at high risk for perceived stigma, as well as to inform epilepsy research in self-management. (C) 2009 Elsevier Inc. All rights reserved.”
“Despite the use of statins for prevention of cardiovascular events, a residual risk remains in part due to persisting abnormalities

on lipids. For decades, WH-4-023 niacin has been used for the management of dyslipidemia, it improves multiple lipid parameters and is the most potent drug available to increase HDL-C. Niacin, either in monotherapy or in combination with other lipid-lowering agents, decreases the CHIR98014 chemical structure risk of cardiovascular events. However, its use is limited by the high incidence of flushing, even with the extensed-release formulation. Laropiprant, a selective antagonist of prostaglandin D2 receptor I, is effective in reducing niacin-induced flushing,

without affecting the lipid effects of niacin. The available data on a single-tablet combination of niacin and laropiprant are promising to allow more patients to achieve the therapeutic niacin dose of 2 g per day in clinical practice. However, the niacin/laropiprant combination does not completely eliminate niacin-flushing side effects and this treatment requires careful instructions to the patient. The ongoing clinical trial, HPS2-THRIVE, will provide important information on the efficacy of extended-release niacin/laropiprant for reducing cardiovascular events, as well as on the long-term safety of this drug.”
“Crimean-Congo hemorrhagic fever (CCHF) is a fatal viral disease that occurs in approximately 30 countries. It has the most extensive geographic range among the tick-borne viruses that affect human health. Recently, a 6-year-old boy presented with complaints of fever, fatigue, and loss of appetite. He revealed a history of tick bite in rural Istanbul three days prior to presentation. A hyperemia was detected at the site of the tick bite.